Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Spectral Medical

DB:SD4
Snowflake Description

Adequate balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SD4
DB
CA$114M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Spectral Medical Inc. focuses on the development and commercialization of treatment for septic shock in North America. The last earnings update was 10 days ago. More info.


Add to Portfolio Compare Print
  • Spectral Medical has significant price volatility in the past 3 months.
SD4 Share Price and Events
7 Day Returns
-0.7%
DB:SD4
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
32.2%
DB:SD4
-13.2%
DE Biotechs
-20.9%
DE Market
SD4 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Spectral Medical (SD4) -0.7% -26.6% -43.2% 32.2% -19.4% -60%
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • SD4 outperformed the Biotechs industry which returned -13.2% over the past year.
  • SD4 outperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
SD4
Industry
5yr Volatility vs Market

Value

 Is Spectral Medical undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Spectral Medical. This is due to cash flow or dividend data being unavailable. The share price is €0.304.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Spectral Medical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Spectral Medical's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:SD4 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in CAD CA$-0.02
TSX:EDT Share Price ** TSX (2020-04-03) in CAD CA$0.5
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Spectral Medical.

DB:SD4 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSX:EDT Share Price ÷ EPS (both in CAD)

= 0.5 ÷ -0.02

-23.22x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Spectral Medical is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Spectral Medical is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Spectral Medical's expected growth come at a high price?
Raw Data
DB:SD4 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -23.22x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Spectral Medical, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Spectral Medical's assets?
Raw Data
DB:SD4 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in CAD CA$0.01
TSX:EDT Share Price * TSX (2020-04-03) in CAD CA$0.5
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:SD4 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSX:EDT Share Price ÷ Book Value per Share (both in CAD)

= 0.5 ÷ 0.01

49.98x

* Primary Listing of Spectral Medical.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Spectral Medical is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Spectral Medical's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Spectral Medical has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Spectral Medical expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-20.6%
Expected annual growth in earnings per share.
Earnings growth vs Low Risk Savings
Is Spectral Medical expected to grow at an attractive rate?
  • Spectral Medical's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Spectral Medical's earnings are expected to decrease over the next 1-3 years, this is below the Germany market average.
  • Spectral Medical's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:SD4 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:SD4 Future Earnings per Share Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts -20.6%
DB:SD4 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 61.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:SD4 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:SD4 Future Estimates Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 13 1
2020-12-31 9 -14 1
2020-04-06
DB:SD4 Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-12-31 3 -3 -5
2019-09-30 4 -2 -3
2019-06-30 4 -1 -2
2019-03-31 3 -2 -3
2018-12-31 4 -2 -2
2018-09-30 3 -3 -4
2018-06-30 3 -3 -4
2018-03-31 4 -3 -4
2017-12-31 4 -4 -4
2017-09-30 4 -5 -4
2017-06-30 4 -7 -6
2017-03-31 3 -9 -8

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Spectral Medical's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • Spectral Medical's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:SD4 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Spectral Medical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:SD4 Future Estimates Data
Date (Data in CAD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 -0.03 -0.03 -0.03 1.00
2020-12-31 -0.01 -0.01 -0.01 1.00
2020-04-06
DB:SD4 Past Financials Data
Date (Data in CAD Millions) EPS *
2019-12-31 -0.02
2019-09-30 -0.01
2019-06-30 -0.01
2019-03-31 -0.01
2018-12-31 -0.01
2018-09-30 -0.02
2018-06-30 -0.02
2018-03-31 -0.02
2017-12-31 -0.02
2017-09-30 -0.02
2017-06-30 -0.03
2017-03-31 -0.04

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Spectral Medical will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Spectral Medical's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Spectral Medical has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Spectral Medical performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Spectral Medical's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Spectral Medical does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Spectral Medical's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Spectral Medical's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Spectral Medical's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Spectral Medical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:SD4 Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 2.87 -4.86 6.19
2019-09-30 3.99 -3.00 4.74 0.11
2019-06-30 4.03 -2.31 4.16 0.11
2019-03-31 3.22 -2.77 4.08 0.11
2018-12-31 3.84 -2.49 5.11
2018-09-30 2.86 -4.01 4.80 0.19
2018-06-30 3.10 -4.16 5.14 0.19
2018-03-31 3.92 -3.80 5.56 0.19
2017-12-31 3.67 -4.08 5.64 0.24
2017-09-30 3.59 -4.02 5.65 0.05
2017-06-30 3.58 -5.80 7.16 0.05
2017-03-31 3.39 -8.15 9.19 0.12
2016-12-31 3.55 -10.15 11.14 0.07
2016-09-30 3.45 -11.43 12.43 0.07
2016-06-30 3.33 -11.29 12.30 0.08
2016-03-31 3.27 -10.20 11.29 0.02
2015-12-31 3.09 -9.52 10.64 0.02
2015-09-30 3.07 -9.68 10.57 0.29
2015-06-30 3.04 -8.59 10.25 0.27
2015-03-31 3.00 -8.64 10.31 0.27
2014-12-31 2.96 -9.49 11.03 0.27
2014-09-30 2.98 -10.68 12.52
2014-06-30 3.01 -11.79 12.94
2014-03-31 2.81 -12.41 13.33
2013-12-31 2.67 -11.31 12.20
2013-09-30 2.52 -9.73 10.53
2013-06-30 2.53 -9.29 10.06

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Spectral Medical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Spectral Medical has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Spectral Medical improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Spectral Medical's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Spectral Medical has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Spectral Medical's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Spectral Medical's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Spectral Medical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Spectral Medical's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Spectral Medical's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Spectral Medical has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Spectral Medical Company Filings, last reported 3 months ago.

DB:SD4 Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 2.26 0.00 1.50
2019-09-30 3.59 0.00 2.98
2019-06-30 4.77 0.00 3.80
2019-03-31 5.40 0.00 4.61
2018-12-31 6.37 0.00 4.52
2018-09-30 5.95 0.00 4.57
2018-06-30 6.62 0.00 5.22
2018-03-31 2.82 0.00 0.98
2017-12-31 2.86 0.00 1.50
2017-09-30 3.44 0.00 2.27
2017-06-30 4.20 0.00 2.91
2017-03-31 5.17 0.00 3.71
2016-12-31 5.82 0.00 5.23
2016-09-30 6.79 0.00 7.18
2016-06-30 9.07 0.00 10.04
2016-03-31 12.47 0.00 12.86
2015-12-31 5.43 0.00 6.41
2015-09-30 7.68 0.00 8.40
2015-06-30 10.42 0.00 10.94
2015-03-31 6.65 0.00 7.07
2014-12-31 8.82 0.00 10.07
2014-09-30 11.23 0.00 11.70
2014-06-30 0.33 0.00 1.44
2014-03-31 2.73 0.00 3.73
2013-12-31 5.70 0.00 7.25
2013-09-30 8.70 0.00 9.04
2013-06-30 11.02 0.00 10.65
  • Spectral Medical has no debt.
  • Spectral Medical has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Spectral Medical has less than a year of cash runway based on current free cash flow.
  • Spectral Medical has less than a year of cash runway if free cash flow continues to reduce at historical rates of -24.7% each year.
X
Financial health checks
We assess Spectral Medical's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Spectral Medical has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Spectral Medical's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Spectral Medical dividends.
If you bought €2,000 of Spectral Medical shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Spectral Medical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Spectral Medical's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:SD4 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:SD4 Future Dividends Estimate Data
Date (Data in CA$) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2020-04-06

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Spectral Medical has not reported any payouts.
  • Unable to verify if Spectral Medical's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Spectral Medical's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Spectral Medical has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Spectral Medical's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Spectral Medical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Spectral Medical has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Spectral Medical's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Paul Walker
COMPENSATION CA$785,747
AGE 70
TENURE AS CEO 19 years
CEO Bio

Dr. Paul M. Walker, MD, PhD, FRCS, has been the Chief Executive Officer and President of Spectral Medical Inc. since April 2001. Dr. Walker serves as the Chief Executive Officer and President of Sepsis, Inc. He served as the Chief Operating Officer of Toronto General Hospital. He served as a Surgeon in Chief and Vice President of the Surgical Directorate of the University Health Network in Toronto, Ontario. He joined Toronto Hospital in 1980 where he practised vascular surgery, critical-care medicine and ran a large research laboratory funded by the Medical Research Council of Canada from 1981 to 1997. He serves as the Chairman of HIO Group Incorporated. He has over 30 years of experience in Canadian healthcare — including as Surgeon-in-Chief and Chief Operating Officer of Toronto General Hospital. From 1990 to 1994, he was Program Director for Critical Care Medicine at the University of Toronto. Dr. Walker was an active vascular Surgeon, Director of the Intensive Care Program and Professor of Medicine and Laboratory Medicine at the University of Toronto. He has been a Director of Spectral Medical Inc. since April 2001. He served as a Director of Liponex Inc. since 2003 and served as a Member of its Scientific Advisory Board. He is the author of over 100 scientific publications. He was accredited as a general surgeon by the Royal College of Physicians and Surgeons of Canada in 1977 and as a vascular surgeon in 1984. Dr. Walker received his MD from the University of Western Ontario, London, Ontario in 1973. He is also a graduate of the Advanced Management Program of the Harvard School of Business in Cambridge, Massachusetts. He completed a PhD in Biochemistry at the University of Gothenburg (Sweden) in 1984.

CEO Compensation
  • Paul's compensation has increased whilst company is loss making.
  • Paul's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the Spectral Medical management team in years:

6.9
Average Tenure
  • The average tenure for the Spectral Medical management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Paul Walker

TITLE
President
COMPENSATION
CA$786K
AGE
70
TENURE
19 yrs

Gualtiero Guadagni

TITLE
Vice President of Sales & Marketing
COMPENSATION
CA$299K
TENURE
6.9 yrs

Chris Seto

TITLE
Chief Financial Officer
TENURE
0.7 yrs
Board of Directors Tenure

Average tenure and age of the Spectral Medical board of directors in years:

10.1
Average Tenure
65
Average Age
  • The average tenure for the Spectral Medical board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Tony Bihl

TITLE
Independent Chairman of the Board
COMPENSATION
CA$84K
AGE
63

Paul Walker

TITLE
President
COMPENSATION
CA$786K
AGE
70
TENURE
19 yrs

Guillermo Herrera

TITLE
Independent Director
COMPENSATION
CA$70K
AGE
65
TENURE
13.6 yrs

Kevin Giese

TITLE
Independent Director
COMPENSATION
CA$59K
TENURE
10.1 yrs

William Stevens

TITLE
Independent Director
COMPENSATION
CA$53K
TENURE
5.6 yrs

Jun Hayakawa

TITLE
Director
TENURE
1.9 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Spectral Medical individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
26. Feb 20 Buy Chris Seto Individual 25. Feb 20 25. Feb 20 15,000 €0.44 €6,592
18. Feb 20 Buy Chris Seto Individual 11. Feb 20 11. Feb 20 22,000 €0.51 €11,218
18. Feb 20 Buy Gualtiero Guadagni Individual 14. Feb 20 14. Feb 20 100,000 €0.51 €50,805
14. Feb 20 Buy Kevin Giese Individual 14. Feb 20 14. Feb 20 50,000 €0.52 €26,099
12. Feb 20 Buy Paul Walker Individual 12. Feb 20 12. Feb 20 400,000 €0.51 €202,188
10. Feb 20 Buy William Stevens Individual 06. Feb 20 06. Feb 20 50,000 €0.26 €12,846
10. Feb 20 Buy Anthony Bihl Individual 06. Feb 20 06. Feb 20 50,000 €0.26 €12,846
11. Feb 20 Buy Chris Seto Individual 07. Feb 20 11. Feb 20 18,000 €0.50 €9,049
11. Feb 20 Sell Debra-Anne Foster Individual 11. Feb 20 11. Feb 20 -72,677 €0.49 €-35,476
11. Feb 20 Buy Debra-Anne Foster Individual 11. Feb 20 11. Feb 20 100,000 €0.26 €25,840
X
Management checks
We assess Spectral Medical's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Spectral Medical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Spectral Medical Inc. focuses on the development and commercialization of treatment for septic shock in North America. The company markets Endotoxin Activity Assay, a rapid diagnostic test for the detection of components of gram negative bacterial cell wall in Europe and Canada; and Toraymyxin, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream in Europe, Canada, and Japan. It also develops, produces, and markets recombinant proteins, antibodies, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies; and develops continuous renal replacement therapy, an open platform for other hemoperfusion cartridges. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was founded in 1991 and is headquartered in Toronto, Canada.

Details
Name: Spectral Medical Inc.
SD4
Exchange: DB
Founded: 1991
CA$74,801,601
228,105,745
Website: http://www.spectraldx.com
Address: Spectral Medical Inc.
135 The West Mall,
Unit 2,
Toronto,
Ontario, M9C 1C2,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSX EDT Common Shares The Toronto Stock Exchange CA CAD 16. Jul 1992
OTCPK EDTX.F Common Shares Pink Sheets LLC US USD 16. Jul 1992
DB SD4 Common Shares Deutsche Boerse AG DE EUR 16. Jul 1992
Number of employees
Current staff
Staff numbers
25
Spectral Medical employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 02:45
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/03/27
Last earnings filing: 2020/03/27
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.